Research programme: stem cell-based therapeutics - International Stem Cell Corporation

Drug Profile

Research programme: stem cell-based therapeutics - International Stem Cell Corporation

Alternative Names: Human parthenogenetic stem cells - International Stem Cell Corporation; Induced pluripotent stem cells - International Stem Cell Corporation; iPS cells - International Stem Cell Corporation; iPSC; Safe iPS cells - International Stem Cell Corporation

Latest Information Update: 17 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator International Stem Cell Corporation
  • Developer International Stem Cell Corporation; University of California at San Francisco
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Pancreatic beta cell replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Blindness; Liver disorders
  • Research Osteoarthritis
  • Discontinued Diabetes mellitus

Most Recent Events

  • 14 Sep 2016 Allele Biotechnology and Pharmaceuticals receives SBIR grant from National Heart, Lung, and Blood Institute
  • 14 Dec 2015 TGA approves IND application for ISC-hpNSC in Parkinson's disease
  • 03 Nov 2015 Cyto Therapeutics signs a Letter of Intent with Royal Melbourne Hospital for conducting phase I/IIa clinical trials for Parkinson's disease in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top